Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of ELVN-002 with Trastuzumab and Chemotherapy for Patients with Advanced HER2+ Solid Tumors, Colorectal Cancer, and Breast Cancer

    Not recruiting

    1 1 1 1
    Belgium France Italy The Netherlands Spain
  • Study on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer

    Not recruiting

    2 1 1 1
    Germany Hungary Italy Spain
  • Study of trastuzumab deruxtecan treatment in patients with advanced HER2-positive breast cancer with or without brain metastases

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark Germany Ireland Italy Poland +2
  • Study on the Effects of Atezolizumab, Trastuzumab, and Pertuzumab in Patients with Early-Stage Triple-Negative or HER2+ Breast Cancer

    Not recruiting

    2 1 1 1
    France
  • Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

    Not recruiting

    2 1 1 1
    Croatia France Italy Spain
  • Study on Trastuzumab Deruxtecan for Patients with Metastatic HER2-Positive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy
  • Study on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment

    Not recruiting

    2 1 1 1
    Belgium France Poland Portugal Spain
  • Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    Austria Belgium Bulgaria Czechia Denmark France +8
  • Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    France
  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Austria Belgium Czechia Finland France Germany +6